engleski

NeuroAD™ System – New treatment approach in Alzheimer's disease

Alzheimer’s disease (AD) is a devastating, terminal disease, a ecting nearly 44 million people worldwide. Currently there are only four pharmacological options for patients that are still being used today and it has been more than a decade since the introduction of any new drugs. Given these limits and the reality that many patients do not like to take the medications and that others may have adverse reactions to the drugs, there is a huge unmet need for new and innovative non-pharmacological treatments as an add-on therapy. e NeuroADTM System is the rst European (CE) approved non- pharmacological treatment for mild to moderate Alzheimer’s disease. is patented, non-invasive treatment uses repetitive transcranial magnetic stimulation (rTMS) in combination with cognitive training to reverse and slow down the progression of the disease, with minimal side e ects. In randomized, double blind, placebo- controlled clinical trials spanning the US, Israel, Europe and Asia, patients have experienced measurable cognitive improvement a er the initial 6- week treatment, with results which may last up to one year. With the NeuroADTM System commercially available across Europe and many areas of the world, Neuronix has completed enrollment for its FDA multi-center clinical trial and seeks FDA clearance to launch the NeuroADTM System and this treatment in the US in 2017. At the University Psychiatric Hospital Vrapče, which is the largest psychiatric hospital in Croatia, we have the oldest Psychogeriatric department (since 1959), and also a new ward for neurocognitive disorders. We plan to be the rst site to purchase the NeuroADTM System and bring this e ective Alzheimer’s disease treatment to Croatia and this region.

Alzheimer's disease; dementia; NeuroAD System; treatment; new; non pharmacological; Croatia

Presented as a poster on CROCAD-16, Tučepi, Croatia, 05– 08.10.2016